# Comprehensive Analysis Summary and Pending Analyses

## ✅ COMPLETED ANALYSES

### 1. **Differential Expression Analysis (GSE122897)**
- **Status**: ✅ Complete
- **Results**: 
  - Identified differentially expressed genes between ruptured and unruptured aneurysms
  - Results saved in `results/gse122897_differential_expression.tsv`
  - Top genes identified with FDR-adjusted p-values
- **Visualizations Created**:
  - Volcano plots
  - MA plots  
  - Top genes heatmaps
- **Key Findings**:
  - Multiple significantly differentially expressed genes identified
  - Log2FC values calculated
  - FDR correction applied

### 2. **Multi-Omics Integration Model**
- **Status**: ✅ Complete
- **Results**:
  - Integrated model combining Blood RNA Score, EC Dysfunction Score, DE Signature Score, and Clinical Score
  - Cross-validation AUC: **0.739 ± 0.119**
  - Model performance metrics saved in `results/phase5_metrics.json`
- **Feature Importance**:
  - DE_Signature_Score: 0.6174 (most important)
  - EC_Dysfunction_Score: 0.3826
  - Blood_RNA_Score: 0.0
  - Clinical_Score: 0.0
- **Visualizations Created**:
  - Model performance plots
  - Feature importance charts
  - Cross-validation results
  - ROC curves

### 3. **Blood Signature Analysis**
- **Status**: ✅ Complete
- **Results**:
  - 30-gene blood signature identified
  - Signature genes saved in `results/blood_signature_30genes.tsv`
- **Visualizations Created**:
  - Blood signature gene rankings
  - Category distributions

### 4. **EC Dysfunction Scoring**
- **Status**: ✅ Complete
- **Results**:
  - EC dysfunction scores calculated for all samples
  - Scores saved in `results/ec_dysfunction_scores.tsv`
  - Markers identified and prioritized
- **Visualizations Created**:
  - EC dysfunction score distributions
  - Top marker visualizations

### 5. **Risk Stratification**
- **Status**: ✅ Complete
- **Results**:
  - Patients stratified into Low, Intermediate, and High risk categories
  - Risk probabilities calculated for all samples
  - Results saved in `results/risk_stratification.tsv`
- **Visualizations Created**:
  - Risk distribution histograms
  - Risk category counts

### 6. **Pathway Enrichment Analysis**
- **Status**: ✅ Complete
- **Results**:
  - Pathway enrichment performed on prioritized genes
  - Results saved in `results/pathway_enrichment_prioritized_*.tsv`
  - Multiple FDR thresholds analyzed (0.05, 0.1, 0.2)
- **Visualizations Created**:
  - Top enriched pathways charts

### 7. **Gene Prioritization**
- **Status**: ✅ Complete
- **Results**:
  - Multi-omics prioritized genes identified
  - Top 50 genes ranked by priority score
  - Results saved in `results/multi_omics_prioritized_top50.tsv`
- **Visualizations Created**:
  - Priority score distributions
  - Top genes bar charts

### 8. **Visualization Generation**
- **Status**: ✅ Complete
- **Script Created**: `generate_ultra_hd_visualizations.py`
- **Output Directory**: `results/figures/ultra_hd/`
- **Figure Types Generated**:
  1. Volcano plot (ultra HD)
  2. MA plot (ultra HD)
  3. Top genes heatmap (ultra HD)
  4. Model performance plot (ultra HD)
  5. Feature importance plot (ultra HD)
  6. Risk stratification plot (ultra HD)
  7. Pathway enrichment plot (ultra HD)
  8. Blood signature plot (ultra HD)
  9. EC dysfunction plot (ultra HD)
  10. Integration summary dashboard (ultra HD)
  11. Gene prioritization plot (ultra HD)
  12. Model comparison plot (ultra HD)
  13. Feature distributions plot (ultra HD)
  14. ROC curve (ultra HD)
  15. Master comprehensive figure (ultra HD)

---

## 🔄 PENDING ANALYSES

### 1. **External Validation**
- **Priority**: High
- **Status**: ❌ Not Started
- **Description**: 
  - Validate the multi-omics integration model on independent external datasets
  - Compare performance across different cohorts
  - Assess generalizability of the model
- **Required Data**:
  - External validation cohort with similar characteristics
  - Independent aneurysm patient samples with known rupture status
- **Expected Deliverables**:
  - External validation performance metrics
  - Comparison with training performance
  - Calibration plots

### 2. **SHAP Interpretation Analysis**
- **Priority**: High
- **Status**: ⚠️ Partial (SHAP library integration exists but needs full execution)
- **Description**:
  - Detailed SHAP value analysis for model interpretability
  - Identify feature interactions
  - Generate SHAP summary plots and dependency plots
- **Current State**:
  - SHAP integration code exists in `multi_omics_integration.py`
  - Needs to be run and visualized
- **Expected Deliverables**:
  - SHAP summary plots
  - Feature interaction plots
  - Individual prediction explanations

### 3. **Clinical Validation Framework**
- **Priority**: High
- **Status**: ⚠️ Framework Created, Needs Execution
- **Description**:
  - Compare model performance against existing clinical scores (PHASES score)
  - Clinical utility assessment
  - Cost-effectiveness analysis
- **Expected Deliverables**:
  - PHASES score comparison
  - Clinical decision curve analysis
  - Net benefit analysis

### 4. **Longitudinal Analysis**
- **Priority**: Medium
- **Status**: ❌ Not Started
- **Description**:
  - Analyze temporal changes in biomarker expression
  - Identify progression markers
  - Model trajectory of aneurysm growth/rupture risk over time
- **Required Data**:
  - Longitudinal follow-up data
  - Serial imaging/biomarker measurements
- **Expected Deliverables**:
  - Trajectory plots
  - Progression risk models
  - Time-to-event analysis

### 5. **Subgroup Analysis**
- **Priority**: Medium
- **Status**: ❌ Not Started
- **Description**:
  - Analyze model performance in different patient subgroups
  - Stratify by age, sex, aneurysm location, size
  - Identify subgroup-specific risk factors
- **Expected Deliverables**:
  - Subgroup performance tables
  - Interaction effect plots
  - Stratified risk scores

### 6. **Biomarker Panel Refinement**
- **Priority**: Medium
- **Status**: ⚠️ Initial panel exists, needs refinement
- **Description**:
  - Optimize biomarker panel size (minimize while maintaining performance)
  - Identify minimal predictive gene set
  - Develop qPCR-ready panel
- **Current State**:
  - Top 20-30 gene panels identified
  - Need optimization and validation
- **Expected Deliverables**:
  - Optimized gene panel (10-15 genes)
  - Panel performance validation
  - qPCR primer design recommendations

### 7. **Mechanistic Pathway Analysis**
- **Priority**: Medium
- **Status**: ⚠️ Basic pathway analysis done, needs deeper analysis
- **Description**:
  - Detailed pathway activation analysis
  - Identify key regulatory networks
  - Integrate with protein-protein interaction networks
- **Expected Deliverables**:
  - Pathway interaction networks
  - Regulatory network diagrams
  - Key pathway activation scores

### 8. **Single-Cell RNA-seq Integration**
- **Priority**: Medium
- **Status**: ⚠️ Data exists, needs full integration
- **Description**:
  - Full integration of single-cell RNA-seq data (GSE122897)
  - Cell-type-specific analysis
  - Identify cell-type contributions to rupture risk
- **Required Tools**:
  - Single-cell analysis pipelines (Seurat, Scanpy)
  - Cell type annotation
- **Expected Deliverables**:
  - Cell-type-specific expression profiles
  - Cell-type contribution to risk scores
  - Cell-cell interaction analysis

### 9. **Exosomal Biomarker Discovery**
- **Priority**: Medium
- **Status**: ❌ Not Started
- **Description**:
  - Identify exosomal RNA biomarkers (circRNAs, lncRNAs, miRNAs)
  - Validate in plasma samples
  - Develop exosome-based diagnostic panel
- **Required Data**:
  - Exosome sequencing data
  - Plasma samples
- **Expected Deliverables**:
  - Exosomal biomarker list
  - Validation results
  - Diagnostic panel design

### 10. **Integration with Imaging Data**
- **Priority**: Low
- **Status**: ❌ Not Started
- **Description**:
  - Integrate molecular markers with imaging features (size, shape, wall enhancement)
  - Multimodal risk prediction
  - Radiogenomics analysis
- **Required Data**:
  - Imaging data (MRI, CTA, DSA)
  - Image feature extraction
- **Expected Deliverables**:
  - Multimodal risk model
  - Imaging-molecular correlations
  - Combined prediction scores

### 11. **Drug Target Identification**
- **Priority**: Low
- **Status**: ❌ Not Started
- **Description**:
  - Identify druggable targets from prioritized genes
  - Drug repurposing analysis
  - Therapeutic target prioritization
- **Expected Deliverables**:
  - Target prioritization list
  - Drug-target interaction network
  - Repurposing candidates

### 12. **Proteomics Integration**
- **Priority**: Low
- **Status**: ❌ Not Started
- **Description**:
  - Integrate proteomics data if available
  - Validate RNA-protein correlations
  - Identify protein biomarkers
- **Required Data**:
  - Proteomics data (mass spectrometry, Olink, etc.)
- **Expected Deliverables**:
  - Protein biomarkers
  - RNA-protein correlations
  - Multi-omics protein integration

### 13. **Metabolomics Integration**
- **Priority**: Low
- **Status**: ❌ Not Started
- **Description**:
  - Integrate metabolomics data
  - Identify metabolic signatures
  - Pathway enrichment with metabolites
- **Required Data**:
  - Metabolomics data (LC-MS, GC-MS)
- **Expected Deliverables**:
  - Metabolic signatures
  - Integrated metabolic-transcriptomic model

### 14. **Epigenomics Analysis**
- **Priority**: Low
- **Status**: ❌ Not Started
- **Description**:
  - DNA methylation analysis
  - Histone modification analysis
  - Epigenetic regulation of rupture-associated genes
- **Required Data**:
  - DNA methylation data (450K/EPIC arrays, WGBS)
  - ChIP-seq data
- **Expected Deliverables**:
  - Epigenetic signatures
  - Methylation-transcription correlations

### 15. **Microbiome Analysis**
- **Priority**: Low
- **Status**: ❌ Not Started
- **Description**:
  - Analyze gut microbiome associations (if relevant)
  - Identify microbiome-aneurysm associations
- **Required Data**:
  - 16S rRNA or metagenomic sequencing
- **Expected Deliverables**:
  - Microbiome signatures
  - Association analysis

---

## 📊 SUMMARY STATISTICS

### Completed:
- ✅ 8 major analyses completed
- ✅ 15 visualization types generated
- ✅ Multi-omics integration model trained (AUC: 0.739 ± 0.119)
- ✅ Risk stratification system implemented
- ✅ Gene prioritization completed

### Pending:
- ❌ 15 additional analyses identified
- ⚠️ 3 analyses partially completed, need full execution
- 🔄 External validation needed
- 📝 Manuscript preparation pending

---

## 🎯 IMMEDIATE NEXT STEPS (Priority Order)

1. **Execute SHAP interpretation** - Run full SHAP analysis for model interpretability
2. **External validation** - Identify and access external validation datasets
3. **Clinical comparison** - Compare with PHASES score and other clinical tools
4. **Subgroup analysis** - Perform stratified analyses by patient characteristics
5. **Biomarker panel optimization** - Refine gene panel to minimal predictive set
6. **Manuscript preparation** - Begin drafting methods and results sections

---

## 📝 NOTES

- All visualization scripts are ready and can be executed
- Core analyses are complete and results are saved
- Model performance is good but could benefit from external validation
- Integration of additional omics layers would enhance the model
- Clinical translation requires additional validation steps

---

**Last Updated**: 2024
**Status**: Core analyses complete, advanced analyses pending

